<DOC>
	<DOCNO>NCT01035749</DOCNO>
	<brief_summary>The purpose study show vaccination single dose GSK Biologicals ' pandemic H1N1 vaccine result immune response meet exceed European Medicines Agency ( EMEA ) Committee Medicinal Products Human Use ( CHMP ) guidance criterion pandemic influenza vaccine .</brief_summary>
	<brief_title>Study GSK Biologicals ' Pandemic Influenza ( H1N1 ) Candidate Vaccine Children Aged 10 Less Than 18 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female child 10 &lt; 18 year age time first vaccination . `` Less 18 year age '' implies inclusion adolescent reach 18th birthday Day 0 , day first vaccine dose protocol . Written inform consent obtain subject 's parent/legally acceptable representative ( LAR ) ; write informed assent obtain subject appropriate . Good general health establish medical history clinical examination enter study . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Subjects investigator believe and/or parent ( ) /LAR comply requirement protocol . Medical history physicianconfirmed infection A/California/7/2009 ( H1N1 ) vlike virus . Previous vaccination time A/California/7/2009 ( H1N1 ) vlike virus vaccine . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject parent ( ) / LAR ( ) unable/unlikely provide accurate safety report . Presence temperature &gt; = 38.0ºC route method , acute symptom great `` mild '' severity schedule date first vaccination . NOTE : The subject may vaccinate later date , provide symptom resolve , vaccination occurs within window specify protocol , eligibility criterion continue satisfy . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Receipt systemic glucocorticoid within 1 month prior study enrollment ( first dose study vaccine ) , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticular inhale glucocorticoid allow . Receipt immunoglobulins and/or blood product within 6 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin eligible dos give 24 hour study vaccination . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Administration license vaccine within 30 day first dose study vaccine , exception seasonal influenza vaccine ( may give within 2 week first dose study vaccine ) . Planned administration A/California H1N1vlike vaccine study vaccine Day 0 Day 189 phlebotomy . Planned administration vaccine foreseen study protocol Day 0 Day 42 first vaccine dose , include seasonal influenza vaccine . Routine childhood vaccination exempt delayed , must administer day H1N1 vaccine candidate . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pandemic influenza</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>H1N1</keyword>
	<keyword>child</keyword>
</DOC>